Steve Krebs, MD
Internal Medicine · Lawrence, KSNPI 1033297122
Payments from drug & device makers
Across 171 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$427
- Lilly USA, LLC$362
- Novo Nordisk$300
- AbbVie$235
- GSK$222
- AstraZeneca$206
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,17099%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 22 | $427 |
| Lilly USA, LLC | 24 | $362 |
| Novo Nordisk | 15 | $300 |
| AbbVie | 11 | $235 |
| GSK | 14 | $222 |
| AstraZeneca | 12 | $206 |
| E.r. Squibb & Sons, L.L.C. | 7 | $167 |
| Bayer | 8 | $135 |
| Nestle Healthcare Nutrition Inc. | 4 | $89 |
| Johnson & Johnson | 4 | $87 |
| Amgen(2 entities) | 4 | $81 |
| Pfizer | 4 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Merck | 4 | $59 |
| Novartis | 3 | $56 |
| Astellas Pharma US Inc | 2 | $50 |
| Nevro Corp. | 3 | $50 |
| Grifols USA, LLC | 2 | $48 |
| Amarin Pharma, Inc. | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| Radius Health, Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Impulse Dynamics (USA) Inc. | 1 | $24 |
| VBI Vaccine (delaware) Inc. | 1 | $24 |
| Medtronic | 1 | $22 |
| Lifescan, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Boston Scientific | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Biogen | 1 | $14 |
How this compares
$3,189 in reported general payments places this provider in the 85th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $74,461 |
| FarxigaDapagliflozin Propanediol | 28 | $37,849 |
| OzempicSemaglutide | 22 | $36,253 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $32,282 |
| XareltoRivaroxaban | 19 | $23,626 |
| JardianceEmpagliflozin | 14 | $23,184 |
| MyrbetriqMirabegron | 16 | $14,200 |
| MounjaroTirzepatide | 12 | $12,420 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $7,137 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 36 | $2,016 |
| Gabapentin | 87 | $1,895 |
| Nebivolol Hcl | 17 | $1,553 |
| Omeprazole | 67 | $1,397 |
| Febuxostat | 14 | $1,368 |
| Atorvastatin Calcium | 177 | $1,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $80 | $74,46167 claims |
| AstraZenecaFarxiga | $206 | $37,84928 claims |
| Novo NordiskOzempic | $300 | $36,25322 claims |
| GSKTrelegy Ellipta | $222 | $32,28243 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $427 | $30,32126 claims |
| Johnson & JohnsonXarelto | $87 | $23,62619 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $14,20016 claims |
| Lilly USA, LLCMounjaro | $362 | $12,42012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Lawrence
- Donna GriebelLawrence$786K
- Martin KankamLeavenworth$63.4M
- Mark HamblinKansas City$5.2M
- Katherine WillinghamTopeka$4.8M
- Raed Al RajabiWestwood$4.5M
- Leslie SpikesKansas City$4.5M
- Michael CoxTopeka$3.4M
- James RuhlmannHutchinson$2.8M
- Scott TeeterTopeka$1.2M
- Shadi HamdehKansas City$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.